Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Bleeding During/Following Surgery Clear all

Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391

View directory record Official record

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Source: ClinicalTrials.gov public record

Updated Dec 28, 2023 · Synced May 22, 2026, 1:30 AM EDT

Completed Not applicable Interventional

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

NCT00320619

View directory record Official record

Conditions: Scoliosis, Kyphosis, Lordosis, Spondylitis, Spinal Stenosis
Interventions: Epsilon-Aminocaproic Acid (EACA), Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older

Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 28, 2016 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

NCT01562158

View directory record Official record

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, activated recombinant human factor VII, placebo; Procedure · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Source: ClinicalTrials.gov public record

Updated Jan 10, 2017 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

NCT02267226

View directory record Official record

Conditions: Congenital Fibrinogen Deficiency
Interventions: Octafibrin; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Jan 14, 2021 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 2 Interventional

Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting

NCT00371215

View directory record Official record

Conditions: Surgical Hemostasis
Interventions: rThrombin; Biological
Lead sponsor: ZymoGenetics; Industry
Eligibility: 2 Years to 75 Years

Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Source: ClinicalTrials.gov public record

Updated Mar 8, 2009 · Synced May 22, 2026, 1:30 AM EDT

Terminated Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

NCT01564563

View directory record Official record

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, placebo, activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more

Source: ClinicalTrials.gov public record

Updated Feb 26, 2017 · Synced May 22, 2026, 1:30 AM EDT